Literature DB >> 23136314

Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

Jinping Xu1, Anne Victoria Neale, Rhonda K Dailey, Susan Eggly, Kendra L Schwartz.   

Abstract

OBJECTIVE: To describe prostate cancer treatment decision making, focusing on knowledge and attitudes toward observation, known as watchful waiting (WW) or active surveillance (AS), and reasons for not choosing WW/AS.
METHODS: Semistructured in-person interviews were conducted with 21 men (14 black; 7 white) with recently diagnosed localized prostate cancer.
RESULTS: All cancers were detected by prostate-specific antigen screening; 14 men had low-risk disease. Nineteen chose surgery or radiation treatment. The majority wanted to "get rid of" or "cure" the cancer by undergoing aggressive therapy, even with awareness of the potential for significant side effects. Most men seemed unaware of the uncertainty/controversies that aggressive treatment may not cure their cancer or improve their survival. Limited knowledge about WW/AS was common, and few remembered WW/AS being presented as a viable option. Rather, many men perceived it as "doing nothing." Some men, who initially were inclined toward WW/AS, yielded to pressure from family, physicians, or both to choose aggressive treatment. Lack of physician support was a significant barrier to WW/AS.
CONCLUSIONS: The observational strategy (WW/AS) was not viewed as a reasonable approach, even for those with low-risk cancer. The desire for aggressive therapy may reflect the complex psychology associated with receiving a diagnosis of cancer and the limited supportive counseling received. Further efforts to better understand and educate patients and physicians may help men make informed and appropriate treatment decisions to maximize quality of life without compromising survival.

Entities:  

Mesh:

Year:  2012        PMID: 23136314      PMCID: PMC4212643          DOI: 10.3122/jabfm.2012.06.120128

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  46 in total

1.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

2.  Patient involvement in surgery treatment decisions for breast cancer.

Authors:  Steven J Katz; Paula M Lantz; Nancy K Janz; Angela Fagerlin; Kendra Schwartz; Lihua Liu; Dennis Deapen; Barbara Salem; Indu Lakhani; Monica Morrow
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

Authors:  Peter R Carroll
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

4.  Geographic and socioeconomic variation in the treatment of prostate cancer.

Authors:  Tracey L Krupski; Lorna Kwan; Abdelmonem A Afifi; Mark S Litwin
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 5.  An analysis of watchful waiting for clinically localized prostate cancer.

Authors:  G D Steinberg; G T Bales; C B Brendler
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

6.  Social learning theory and the Health Belief Model.

Authors:  I M Rosenstock; V J Strecher; M H Becker
Journal:  Health Educ Q       Date:  1988

7.  Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

Authors:  J W Moul; T H Douglas; W F McCarthy; D G McLeod
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

8.  Narrowing the options: the process of deciding on prostate cancer treatment.

Authors:  M E O'Rourke
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

Review 9.  Update on watchful waiting for prostate cancer.

Authors:  Mohamad E Allaf; H Ballentine Carter
Journal:  Curr Opin Urol       Date:  2004-05       Impact factor: 2.309

10.  Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina.

Authors:  W Demark-Wahnefried; J M Schildkraut; C E Iselin; E Conlisk; A Kavee; T E Aldrich; E J Lengerich; P J Walther; D F Paulson
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

View more
  36 in total

1.  Physician variation in management of low-risk prostate cancer: a population-based cohort study.

Authors:  Karen E Hoffman; Jiangong Niu; Yu Shen; Jing Jiang; John W Davis; Jeri Kim; Deborah A Kuban; George H Perkins; Jay B Shah; Grace L Smith; Robert J Volk; Thomas A Buchholz; Sharon H Giordano; Benjamin D Smith
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

2.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

3.  Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.

Authors:  Ronald E Myers; Amy E Leader; Jean Hoffman Censits; Edouard J Trabulsi; Scott W Keith; Anett M Petrich; Anna M Quinn; Robert B Den; Mark D Hurwitz; Costas D Lallas; Sarah E Hegarty; Adam P Dicker; Charnita M Zeigler-Johnson; Veda N Giri; Hasan Ayaz; Leonard G Gomella
Journal:  J Cancer Educ       Date:  2018-02       Impact factor: 2.037

4.  Quality of life and fear of disease progression are associated with aspects of health literacy in men with prostate cancer from Germany.

Authors:  Marius Haack; Silke Kramer; Gabriele Seidel; Marie-Luise Dierks
Journal:  Support Care Cancer       Date:  2019-08-31       Impact factor: 3.603

5.  askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.

Authors:  Gregory B Auffenberg; Khurshid R Ghani; Shreyas Ramani; Etiowo Usoro; Brian Denton; Craig Rogers; Benjamin Stockton; David C Miller; Karandeep Singh
Journal:  Eur Urol       Date:  2018-10-11       Impact factor: 20.096

6.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.

Authors:  Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor
Journal:  Med Decis Making       Date:  2019-10-21       Impact factor: 2.583

7.  The importance of perceived stress management skills for patients with prostate cancer in active surveillance.

Authors:  Betina Yanez; Natalie E Bustillo; Michael H Antoni; Suzanne C Lechner; Jason Dahn; Bruce Kava; Frank J Penedo
Journal:  J Behav Med       Date:  2014-09-19

8.  Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer.

Authors:  Kathleen D Lyons; Hsin H Li; Emily M Mader; Telisa M Stewart; Christopher P Morley; Margaret K Formica; Scott D Perrapato; John D Seigne; Elias S Hyams; Brian H Irwin; Terry Mosher; Mark T Hegel
Journal:  Am J Mens Health       Date:  2016-07-07

9.  Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.

Authors:  Scott P Kelly; Stephen K Van Den Eeden; Richard M Hoffman; David S Aaronson; Tania Lobo; George Luta; Amethyst D Leimpter; Jun Shan; Arnold L Potosky; Kathryn L Taylor
Journal:  J Urol       Date:  2016-04-14       Impact factor: 7.450

10.  Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.

Authors:  Jinping Xu; James Janisse; Julie J Ruterbusch; Joel Ager; Joe Liu; Margaret Holmes-Rovner; Kendra L Schwartz
Journal:  Ann Fam Med       Date:  2016-05       Impact factor: 5.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.